

PHAXIAM



PHAXIAM

---

# Building a Global Leader in Severe Infections Therapies

---

December 2024



# Agenda

1. **Global Context**
2. **PHAXIAM Differentiation**
3. **Development Strategy**
4. **Communication & Financing**



# Experienced & Complementary Leadership Team

Thibaut du Fayet  
CEO



Pascal Birman, MD  
CMO



Frédéric Mathat  
CFO



Jérôme Bailly  
CQO / CTO



Cindy Fevre  
CSO

Pherecydes and Erytech merged to build  
**PHAXIAM**  
Leveraging on Complementary Capabilities from both Executive Teams




# Phages Therapy: A Fast-emerging Large Targeted Addressable Market in EU / US

## Significant Unmet Medical Needs

- Deaths from resistant bacterial INFECTIONS reaching in 2024 ~ 550K patients in EU + US: ~250K (EU) and ~300K<sup>(4)</sup> (US) (Lancet<sup>(2)</sup>, sept 2024)
- Upwards of 8.4 million patients experience every year unresolved resistant bacterial/ difficult-to-treat INFECTIONS in high income countries: EU ~3.7m / US ~4.7m (Lancet<sup>(2)</sup>, sept 2024)
- Phages therapy applications will range from treating “difficult-to-treat” patients to “last-resort / death” patients → TAM<sup>(2)</sup> in EU and US ~ 600K patients


TAM<sup>(2)</sup> Estimate for Phages ESKAPEE<sup>(1)</sup> therapy in EU+US → ~ 600K patients / year




(1) ESKAPEE = most important pathogens covering ~90% of severe resistant infections: E. coli, S. aureus, K. Pneumonia, A. baumannii, P. aeruginosa, E. faecium, Enterobacter  
 (2) Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 (Lancet, Sept 2024)  
 (3) Targeted Addressable Market  
 (4) Estimated – internal estimation



# Phage Therapy, a Solution for Resistant Infections



**Bacteriophages:**  
viruses, natural  
predators of  
bacteria



- Unique mode of action**
- ◆ **Specificity**
  - ◆ **Speed**  
(less than 45 min)
  - ◆ **Self-replication** down to the last bacterium

**Phage Therapy allows SIMPLE, EFFECTIVE and WELL-TOLERATED treatments**

# The Strong Momentum of Phage Therapy

<b>INCREASING IMPACT</b> of difficult-to-treat resistant infections Rising concern among public authorities and medical community
High safety and promising clinical benefits from <b>REAL-LIFE</b> treatments Increased probability of success from early clinical evidence
Active collaboration with <b>REGULATORY AGENCIES</b> Strong support / Clear development guidelines / Accelerated paths
<b>GMP STANDARDIZATION &amp; CMC</b> developments Robust GMP processes / Well characterized phages
Better understanding of resistance mechanisms <b>NEW TOOLS</b> to address potential emergence of phage resistance



**CRITICAL NEEDS FOR ALTERNATIVE TECHNOLOGIES**



**PROMISING REAL-LIFE CLINICAL DATA**



**ATTRACTIVE REGULATORY CONTEXT**



**MATURITY OF THE TECHNOLOGY**



**SOLUTIONS TO POTENTIAL RESISTANCE**

**Phage Therapy is a TOP-10 INNOVATION to be developed according to the 2023 World Economic Forum**



# Leading Phage Therapy Platform

Leading Edge in Clinical Development

Regular Interactions with Regulatory Agencies

Strong internal R&D, CMC & GMP Capabilities

Proprietary PHAGOGRAM® IVD Solution

Large Phage Bank for the most critical bacterial Infections

Strong IP with 87 patents filed

**PHAXIAM**

*Developments within a regulatory framework validated by key health authorities*

**ansm** EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

**FDA**  
U.S. Food and Drug Administration

---

*Network of prestigious scientific partners*



Institut Pasteur Crioac GSO

**INRA**  
SCIENCE & IMPACT **BIOASTER**  
MICROBIOLOGY TECHNOLOGY INSTITUTE



# Real-life Clinical Data From ~120 Treated Patients

- STRONG SUPPORT from Regulatory Authorities & >15 hospitals
- SEVERAL ROUTES OF ADMINISTRATION TESTED, including local, intravenous, nebulisation, ...
- 7 DIFFERENT INDICATIONS TREATED with a majority of PJI



**PROMISING CLINICAL ACTIVITY RESULTS**  
(First 77 patients evaluated)  
2020-2024

- EXCELLENT RESULTS observed in reported cases: safety + clinical benefit
- Several PUBLICATIONS

**~ 80% CONTROL RATE of infection @3months for PJI Patients (n=41)**  
**VERY PROMISING Data in « hard to treat » population**  
(very severe infections - 2<sup>nd</sup>/3<sup>rd</sup> line antibiotics)



# AAC\* Regulatory Status from French Authority (June 2022)



COMPASSIONATE  
ACCESS  
AUTHORIZATION  
(AAC)

## SOURCE OF REVENUES

To be extended to OTHER AAC\* INDICATIONS  
Process towards an EARLY ACCESS AUTHORIZATION  
To be extended to ORPHAN STATUS


An Important First Step for MARKET ACCESS in EUROPE



3- Development Strategy

# Strong Demand From Physicians Opens A Complementary Market Access Business Model

- (1) PTMP = Pre-defined (standardized) finished product consisting of one or more bacteriophage strains
- (2) IPT = Phages Selected within a Pre-existing GMP Phages portfolio based on Phagogram outcomes
- (3) AAC = Authorization for Compassionate Access → **Compassionate Use (CU)**
- (4) Market Authorization
- (5) **Medicinal Product prepared in a Pharmacy in accordance with a medical prescription for an Individual Patient**



- Critical medical needs + No available registered product
- Phages positive real-life clinical data
- EMA concept paper

The Co-existence Of PTMP and IPT Regulatory Framework Mirrors Those Already Implemented in The Allergens Therapeutic Domain



3- Development Strategy

# PTMP and IPT Access Will Co-exist Concurrently In Various European Countries


PTMP

IPT



**Consequently, PHAXIAM seeks to position itself to:**

1. Capitalise on its first mover advantage in the strategically-important emerging IPT model, where market access can start as soon as 2026,
2. Leverage on its existing capabilities in PTMP to secure Conditional Marketing Approval (CMA) by H2 2027.



(1) IPT model = Phages Selected within a Pre-existing GMP Phages portfolio based on Phagogram outcomes  
 (2) PTMP model = Pre-defined (standardized) finished product consisting of one or more bacteriophage strains



# PHAXIAM Has Strong Clinical Development and Market Access Capabilities in the PTMP<sup>(1)</sup> Model

Phages Therapy Medicinal Product (PTMP<sup>(1)</sup>)



- Strong push from FDA / EMA to seek robust clinical POC in RCTs + Based on a EU Pharmacopeia monograph (March 24)
- Recent FDA IND clearance for GLORIA Phase II
- Large hospitals & KOLs network in EU/US, leveraging on ongoing clinical trials: PhagoDAIR (15 EU sites), GLORIA (35 EU sites + 10 US sites)
- PHAXIAM AAC<sup>(2)</sup> (Compassionate Use) Revenues to be extended to other indications

3 Main Pathogens Covered in Clinic

- **S. Aureus** → PJI Pilot Trial, GLORIA PJI Phase II, Endocarditis Phase I PK, PhagoPIED Phase II (IST)
- **P. aeruginosa** → *PyoPhaneb Phase II POC (IST)* - to be initiated
- **E. coli** → Phase I PK - to be initiated



Clinical Strategy Value Drivers

- ✓ Relevant choice of Clinical indications (PJI) & clinical design to maximize Clinical POC for Phages
- ✓ Accelerated registration through CMA / Early Access in EU & US leveraging on Real-life compassionate clinical data

(1) Pre-defined (standardized) finished product consisting of one or more bacteriophage strains  
 (2) AAC = Authorization for Compassionate Access → **Compassionate Use (CU)**



# An Ambitious Clinical Development Strategy

## Target High-Value Indications

Severe Resistant Infections with High unmet medical needs  
high mortality rate / high budget impacts → claims high prices

## Accelerate the Path to Global Registration

Launch the 1<sup>st</sup> global randomized Phase 2 study at international scale in PJI\*  
Leverage on potential Early access pathway (after Phase 2)

## Diversify Portfolio

Target several Life-Threatening Infections (Endocarditis, VAP\*\*, ...)  
Target several Virulent & Resistant Bacteria (*E. coli*, *P. aeruginosa*, ...)


\* Prosthetic Joint Infections

\*\*Ventilated-acquired Pneumopathies



# A Balanced Clinical Portfolio

PTMP



IST: investigator sponsored study

Recruiting

To be initiated

Scheduled

R Clinical data



# PJI, A Strategic Indication For PHAXIAM

- Relatively High incidence: ~50-60K PJI\* (US/EU5; 2027)
- Very High economic burden (cost ~ \$150K in US, €50-70K in EU)
- Most advanced player in EU and US (APT stopped, Armata 18 months behind)
- Clear leadership → 1<sup>st</sup> to Market

1  
**Attractive indication**

3  
**Strong competitive position**

**PJI\* Strategic indication**

2  
**High unmet medical need**

4  
**Highest probability of robust POC for Phages**


- Rare & devastating complication
- 50% failure rate with DAIR\*\*
- High risk of re-infection (60%), amputation (~11%), mortality (25% at 5 years)
- Derisked by Real-life Compassionate experience
- Local route of administration

**Unique and leadership position in the strategic PJI indication**



# GLORIA -first global Phase 2 POC\* clinical study of phages in PJI

A Randomized, Comparative, Double-Blind, Clinical Study to Evaluate the Efficacy and Safety of Phage Therapy in Patients With Osteoarticular Knee or Hip Infection (PJI) Due to Staphylococcus aureus, with the Indication of DAIR



\*Consent Signing  
\*\* Before injection  
\*\*\*During the DAIR or no more than 14 days after the DAIR

- Primary endpoint: Safety; Efficacy (% of patients with clinical cure at M3)
- The GLORIA study is the most strategic clinical trial for PHAXIAM



## Preparation of The GLORIA Study

- ◆ Positive and consistent feedback from the FDA (pre-IND meeting) and EMA (scientific advice)
- ◆ Regulatory filings → Approval obtained from FDA in Q4 2022, expected from EMA and MRHA in early Q1 2025
- ◆ Sites selection ongoing: ~45 sites and countries (FR, ESP, GER, NLD, ITA, UK, US)
- ◆ Launch of the clinical study in Q1 2025, clinical results expected in Q3 2026

- Progress in line with our objectives
- GLORIA Is Our Most Important Asset, Having The Highest Priority



# Expected Major Short term Clinical Catalysts

**CLINICAL  
&  
REGULATORY**





# Near Term Commercial Opportunities Arise From the Emergence of the Individualized Phages Therapy (IPT<sup>(1)</sup>) Market Access Model

Strong Demand from Physicians



- **High unsatisfied clinical needs** → new solutions to address morbidity / mortality induced by severe resistant infections, when the PTMP<sup>(2)</sup> model cannot address clinical needs, as no Medical Products are available
- **Promising clinical evidence** from hundreds of successful compassionate treatments in key reference hospitals across EU

«Push» from Regulatory Stakeholders (EMA) & National Bodies



- EMA Concept paper Guidelines**  
→ Regulatory landscape evolving, making a special case on bacteriophages "**Named-Patient Use Program**" (NPP)
- **Phages Therapy Medicinal Product:** predefined (standardised) finished product consisting of one or more bacteriophage strains → **Major requirements for well-conducted RCTs**
- +
- **Individualized Phages Therapy (IPT)** → Delineate context of clinical use where Medical Products cannot be used / are not available



**Individualized Phages Therapy (IPT)**

- **Magistral Preparation / Compounding with GMP Phages**
- **Pre-requisite for Regulatory Validation per country** (e.g. Exemption granted in Belgium)
- **Based on a Diagnostic Test** (Phagogram - CE marked)
- **Selection of Phages drawn from a pre-existing GMP Phages portfolio**

(1) IPT model = Phages Selected within a Pre-existing GMP Phages portfolio based on Phagogram outcomes  
 (2) Pre-defined (standardized) finished product consisting of one or more bacteriophage strains



# For IPT<sup>(1)</sup>, PHAXIAM Is Targeting As A 1<sup>st</sup> Priority European Countries Familiar with Magistral Preparation

## UK

- Strong interest from Physicians for Phages
- Magistral preparation concept / Compounding very much developed
- Regulatory constraint today → to be discussed and validated by MHRA for general use
- Solution funded by national / regional / hospital envelops

## FRANCE


- Strong interest from Physicians for Phages
- Magistral preparations less used than before / reduced number of compounding organisations
- AAC process in place as Compassionate Use

## SPAIN

- Strong interest from Physicians for Phages
- Magistral preparations progressively disappeared / not a common practice

## NORDIC

- Strong interest from Physicians for Phages
- Magistral preparation / Compounding common practice



## BELGIUM

- Strong interest from Physicians for Phages
- Magistral preparation common practice benefiting from an exemption

## NETHERLANDS

- Strong interest from Physicians for Phages
- Magistral preparation / Compounding developed

## GERMANY

- Strong interest from Physicians for Phages
- Magistral preparation/compounding feasible and standard practices

## ITALY

- Physicians want to use Phages
- Magistral preparation commonly used / large compounding community existing

Increasing Interest From Physicians For Phages All Over Europe  
Magistral Preparation / Compounding Are Common Practices In Northern Europe

(1) IPT model = Phages Selected within a Pre-existing GMP Phages portfolio based on Phagogram outcomes  
 (2) Pre-defined (standardized) finished product consisting of one or more bacteriophage strains




# PHAXIAM Will Deliver IPT to Patients in Key Reference Hospitals As Soon As 2026

IPT

## Actions Plan

- Obtain Local regulatory approval (national / regional) for magistral preparation (leveraging on existing exemption)
- Develop the EU network within reference hospitals (physicians, pharmacists) to be extended to smaller hospitals
- Set-up locally Supply chain and Diagnostic capabilities → Phagogram to be transferred



## Value Drivers

- Average Selling Price of ~€20-25K (EU)
- Treatment invoiced at a local/hospital level, Regional level in some countries
- HTA/Payor negotiation in a 2nd step leveraging on KOL's concerted efforts to support creation of reimbursement codes, at local / national levels



# PTMP And IPT Models Are Synergistic Market Channels With Largely Overlapping Requirements

PTMP  
IPT

## Paneuropean Specialty Pharma in Critical Care

### Individualized Phages Therapy (IPT)

- TAM<sup>(1)</sup> in EU / US ~ 600K patients, of which ~**250 K patients in EU**
- A Fast-emerging Large Market of > ~ **€10bn (EU+US)**
- Conservative Average Selling Price of ~**€20-25K (EU)**
- Not subject to any clinical development risk
- **EU market access Scale-up to reach**
  - ~1K pts / 30 hospitals in 2027; Potential Sales → **€20m**
  - ~7-8K pts / 100 hospitals in 2030; Potential Sales → **~€150m**
- Conservative 2030 Commercial Target is limited to ~3% of TAM<sup>(1)</sup>

- Fully integrated platform including R&D, GMP manufacturing
- Strong relationships with KOLs & Physicians
- Presence in major reference hospitals in EU
- Strong relationships with Regulatory authorities across EU / US
- Diagnostic robust solution in place & potential future reference method
- Market Access capabilities

### Phage Therapy Medicinal Product (PTMP)

- **AAC (Compassionate Use) Potential Sales → ~ €4m in 2027** (PJI + other indications)
- **PJI (lead clinical indication)**
  - TAM(1) in EU/US ~ 40K pts / year
  - Average Selling Price of ~ €20-25K (EU) and ~€25-30K (US)
  - Seeking Conditional Market Approval (CMA) / Early access pathways in H2 2027
  - **PJI CMA Potential Sales → ~ €8m in 2027; €90-100m in 2030**

Synergies Are Reducing The Investments Requirements To Scale-up The IPT Model



PTMP

IPT

# Emerging Paneuropean Specialty Pharma in Critical Care Targeting Positive FCF<sup>(1)</sup> AND Profitability From 2027

## Paneuropean Specialty Pharma in Critical Care

### Individualized Phages Therapy (IPT)

- TAM<sup>(1)</sup> in EU / US ~ 600K patients, of which ~250 K patients in EU
- A Fast-emerging Large Market of > ~ €10bn (EU+US)
- Conservative Average Selling Price of ~€20-25K (EU)
- Not subject to any clinical development risk
- **EU market access Scale-up to reach**
  - ~1K pts / 30 hospitals in 2027; Potential Sales → €20m
  - ~7-8K pts / 100 hospitals in 2030; Potential Sales → ~€150m
- Conservative 2030 Commercial Target is limited to ~3% of TAM<sup>(1)</sup>

Fully integrated platform including R&D, GMP manufacturing

Strong relationships with KOLs & Physicians

Presence in major reference hospitals in EU

Strong relationships with Regulatory authorities across EU / US

Diagnostic robust solution in place & potential future reference method

Market Access capabilities

### Phage Therapy Medicinal Product (PTMP)

- **AAC (Compassionate Use) Potential Sales → ~ €4m in 2027** (PJI + other indications)
- **PJI (lead clinical indication)**
  - TAM(1) in EU/US ~ 40K pts / year
  - Average Selling Price of ~ €20-25K (EU) and ~€25-30K (US)
  - Seeking Conditional Market Approval (CMA) / Early access pathways in H2 2027
  - **PJI CMA Potential Sales → ~ €8m in 2027; €90-100m in 2030**

**PHAXIAM'S Market Access Strategy Is To Rely On Two Concurrent Commercial Pillars: IPT (magistral preparation) and PTMP (ACC + PJI CAM)**



# PHAXIAM, An Emerging Specialty Pharma In Critical Care

- Millions of patients experience every year unresolved resistant bacterial/ difficult-to-treat infections.
- Facing this critical medical need, there is strong demand from KOLs /Physicians for Phages therapy.
- Concurrently with its classical clinical development pathway (Phages Therapy Medical Product=PTMP), EMA has opened the market for the commercialization of Individualized Phages Therapy (IPT) magistral preparations.
- PTMP and IPT Models are complementary and synergistic approaches that can be managed by PHAXIAM with limited additional resources.
- PHAXIAM will benefit greatly from these two complementary commercial pillars:
  - IPT with very large potential that will secure short term revenues (2026-2030),
  - PTMP with already existing AAC Revenues, then potential conditional market approval (CMA) from H2 2027.
- PTMP and IPT form together a self-reinforcing virtuous cycle for Phages therapy:
  - Commercial success in IPT will help finance PTMP programs and facilitate rapid uptake of future approved medicinal products,
  - Success (clinical validation) in PTMP will help broaden clinical and market acceptance of IPT in areas not yet addressable by PTMP.
  - This is strategically important because PHAXIAM is the only competitor with the capabilities to succeed in both markets

**PHAXIAM targets positive Free Cash Flow and Profitability from 2027**



## Financial Position & Objectives

- Major shareholders (equity share): BPI (25%), Auriga / Elaia (8%), Go Capital (5%)
- Listed @Euronext: valuation of €18m
- Capital increase of €7.8m in June 2024
- Cash Runway into March 2025
- Financing
  - Non-dilutive funding (EU, France, Region)
  - Dilutive funding: Private placement in January 2025, targeting €15m; use of proceeds: *GLORIA study conduct (1<sup>st</sup> global EU/US study in PJI\* and Phage therapy) + other clinical studies*

**Till The Market PHAXIAM Still Needs €15-20m To Be Raised In Equity**



Thanks | PHAXIAM



# Reinforced interest in Phage Therapy

Major Commitment from Top Tier US investors in March 2024



Purchase agreement with a \$50m financing led by Top tier investor base, incl. Deerfield and Orbimed




Armata Pharmaceuticals has recently announced a \$35m refinancing with Innoviva

**Growing attractiveness of the phage-therapy field to leading investors**



# Key Technology Assets for PHAXIAM Treatments

- 1 SELECT** phages to maximize breadth of repertoire  
Internal PHAXIAM Technology and Expertise
- 2 PRODUCE** large scale GMP batches of high purity  
Internal PHAXIAM process development Capabilities and Expertise  
Industrial partnership to produce “off-the-shelf” GMP-grade phages
- 3 TEST PHAGOGRAM** for a precision therapy  
PHAXIAM proprietary IVD Test
- 4 DISTRIBUTE** personalized therapeutics to patients’ bed  
Supply chain in place with a few days leadtime



Discovery, Screening, Characterization, GMP production, Testing, Distributing



# Manufacturing & Logistics strategic capabilities

In-house process development & analytical science

In-house highly purified phages manufacturing


**Strategic partnership with MB Pharma (CMO, EU) to manufacture GMP bacteriophages clinical batches**

**Pharmaceutical supply chain mastered to ensure robust and short lead time clinical supply (clinical studies, AAC, ...)**

## Major achievements



- > 35 GMP clinical batches produced
- Low Manufacturing COGS
- Available capacity till early market launch
- Short supply lead time (> 1 week)




**Manufacturing & Logistics Capacities Fit to Address future Clinical Demand**



# Targeting High-value Resistant Infections

Life-Threatening Conditions  
 Potential Orphan Status  
 Indications  
 The most severe Hospital-  
 Acquired and Resistant  
 Infections





# Additional Clinical Studies

TRIALS	STATUS AND PROGRESS
<p><b>Endocarditis Infections (EI)</b></p> <p><b>Staph. aureus</b></p> <p><b>Phase I PK</b></p>	<p><b>Demonstration for IV indications before Registration Study</b></p> <ul style="list-style-type: none"> <li>Resistant infections in cardiac chambers and valves</li> <li>IV-administered Phages</li> </ul> <p><u>Key milestones</u> : First Patient-In, April 2024</p>
<p><b>Complex Urinary Tract Infections (cUTI)</b></p> <p><b>E. coli</b></p> <p><b>Phase I PK</b></p>	<p><b>Demonstration for intra-bladder administration before Registration Study</b></p> <ul style="list-style-type: none"> <li>cUTI with resistant E. Coli infections in the bladder</li> <li>Phages administered locally into the bladder</li> </ul> <p><u>Key milestones</u> : ANSM study validation in April 2024</p>